>Like big pharma, AMGN will be subject to generic competition, and it would seem that the market is already taking this risk into account<
The market is taking this into account to some degree, but I think the downside from biogenerics is going to be more pervasive than most AMGN investors probably do. Regards, Dew
News 
Market Data 
Discover 
